Cover Image
市場調查報告書

細菌性陰道炎:開發平台分析

Bacterial Vaginosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245975
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
細菌性陰道炎:開發平台分析 Bacterial Vaginosis - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 61 Pages
簡介

細菌性陰道炎(BV)是由於陰道內細菌異常增生而發病的發炎性疾病的一種。主要的症狀有陰道內部發癢,及排尿時燒灼感,陰道分泌物的水分增加·稀薄化等。主要的治療藥有抗生素等。

本報告提供全球各國治療細菌性陰道炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

細菌性陰道炎概要

治療藥的開發

  • 細菌性陰道炎開發中產品:概要
  • 細菌性陰道炎開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Alfa Wassermann S.p.A
  • AmVac AG
  • Osel Inc.
  • Starpharma Holdings Limited
  • Symbiomix Therapeutics, LLC

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AMV-100
  • astodrimer
  • benzoyl peroxide
  • LACTIN-V
  • Peptide for Bacterial Vaginosis
  • rifaximin
  • secnidazole

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8231IDB

Summary

Global Markets Direct's, 'Bacterial Vaginosis - Pipeline Review, H2 2016', provides an overview of the Bacterial Vaginosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis
  • The report reviews pipeline therapeutics for Bacterial Vaginosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bacterial Vaginosis therapeutics and enlists all their major and minor projects
  • The report assesses Bacterial Vaginosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bacterial Vaginosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bacterial Vaginosis Overview
  • Therapeutics Development
    • Pipeline Products for Bacterial Vaginosis - Overview
    • Pipeline Products for Bacterial Vaginosis - Comparative Analysis
  • Bacterial Vaginosis - Therapeutics under Development by Companies
  • Bacterial Vaginosis - Therapeutics under Investigation by Universities/Institutes
  • Bacterial Vaginosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bacterial Vaginosis - Products under Development by Companies
  • Bacterial Vaginosis - Products under Investigation by Universities/Institutes
  • Bacterial Vaginosis - Companies Involved in Therapeutics Development
    • Alfa Wassermann S.p.A
    • AmVac AG (Inactive)
    • Evofem, Inc.
    • Osel, Inc.
    • Starpharma Holdings Limited
    • Symbiomix Therapeutics, LLC
  • Bacterial Vaginosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Amphora - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMV-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • astodrimer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benzoyl peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LACTIN-V - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifaximin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • secnidazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • subtilosin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOL-463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bacterial Vaginosis - Dormant Projects
  • Bacterial Vaginosis - Discontinued Products
  • Bacterial Vaginosis - Product Development Milestones
    • Featured News & Press Releases
      • May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing
      • May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis
      • Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis
      • Jan 11, 2016: Evofem Holdings Announces Successful Completion of Pre-IND Meeting for Amphora
      • Oct 14, 2015: Additional US Patent granted for VivaGel BV
      • Sep 24, 2015: EU Marketing Approval Granted for VivaGel BV
      • Sep 21, 2015: Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food
      • Aug 27, 2015: Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation
      • Aug 06, 2015: Symbiomix Therapeutics' First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG
      • Jun 09, 2015: Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis
      • May 05, 2015: Symbiomix Therapeutics Announces Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis
      • Mar 04, 2015: Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated
      • Nov 21, 2014: SYM-1219 Chosen as one of the "Top Infectious Disease Projects" to Watch by Therapeutic Area Partnerships
      • Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis
      • Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bacterial Vaginosis, H2 2016
  • Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Bacterial Vaginosis - Pipeline by Alfa Wassermann S.p.A, H2 2016
  • Bacterial Vaginosis - Pipeline by AmVac AG (Inactive), H2 2016
  • Bacterial Vaginosis - Pipeline by Evofem, Inc., H2 2016
  • Bacterial Vaginosis - Pipeline by Osel, Inc., H2 2016
  • Bacterial Vaginosis - Pipeline by Starpharma Holdings Limited, H2 2016
  • Bacterial Vaginosis - Pipeline by Symbiomix Therapeutics, LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bacterial Vaginosis - Dormant Projects, H2 2016
  • Bacterial Vaginosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bacterial Vaginosis, H2 2016
  • Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top